Top

Published in:

01-06-2013 | Research Article

RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice

Authors: Jibin Yao, Mingxu Da, Tiankang Guo, Yaoxing Duan, Yongbin Zhang

Published in: Tumor Biology | Issue 3/2013

Abstract

Overexpression of vascular endothelial growth factor-C (VEGF-C) has been implicated as a critical molecular signal in tumor development by promoting intratumoral lymphangiogenesis. The aim of this study was to explore whether small hairpin RNA (shRNA) targeting VEGF-C could inhibit gastric cancer lymphangiogenesis and tumor growth. Plasmid-mediated expression of VEGF-C–shRNA was employed to silence VEGF-C gene expression in human SGC-7901 cell lines. The inhibition of the target gene expression was quantified by real-time quantitative polymerase chain reaction, Western blotting, and enzyme-linked immunosorbent assay. In vitro, the cell viability was determined by MTT assay, flow cytometry analysis, and migration assay. After VEGF-C knockdown was confirmed, the stable cells were inoculated into nude mice. Tumor growth, lymph vessel density (LVD), and microvascular density were compared for mice administered either VEGF-C–shRNA or control. VEGF-C–shRNA causes effective and specific downregulation of VEGF-C expression (P < 0.05). The migration activity of SGC-7901 cells was attenuated in vitro (P < 0.05). Tumor growth rate and LVD was suppressed in vivo (P < 0.05). VEGF-C–shRNA effectively suppressed gastric cancer cell migration in vivo, retards tumorigenicity, and lymphangiogenesis in nude mice.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi:10.3322/canjclin.55.2.74.PubMedCrossRef

Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15. doi:10.1016/s0140-6736(03)13975-x.PubMedCrossRef

Kurtz JE, Dufour P. Evolving standards of care in advanced gastric cancer. Future Oncol. 2011;7(12):1441–50. doi:10.2217/fon.11.115.PubMedCrossRef

Lordick F, Schumacher G, Becker-Schiebe M. Gastric cancer—still many questions to be solved. MEMO. 2011;4(2):71–4.CrossRef

Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3:257–66. doi:10.2147/CMR.S12713.PubMedCrossRef

Stoffel A. Targeted therapies for solid tumors: current status and future perspectives. BioDrugs. 2010;24(5):303–16. doi:10.2165/11535880-000000000-00000.PubMedCrossRef

Nagahashi M, Ramachandran S, Rashid OM, Takabe K. Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol. 2010;16(32):4003–12.PubMedCrossRef

Da MX, Wu XT, Wang J, Guo TK, Zhao ZG, Luo T, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39(1):92–9. doi:s0140-6736(03)13975-x/j.arcmed.2007.06.021.PubMedCrossRef

Zhu P, Zhang J, Chen Q, Wang J, Wang Y. Expression of vascular endothelial growth factor-C in gastric carcinoma and the effect of its antisense gene transfection on the proliferation of human gastric cancer cell line SGC-7901. Am J Surg. 2012;204(1):78–83. doi:s0140-6736(03)13975-x/j.amjsurg.2011.06.056.PubMedCrossRef

10.

Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T. Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology. 2005;52(62):629–32.PubMed

11.

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61(5):1786–90.PubMed

12.

Shi X, Chen G, Xing H, Weng D, Bai X, Ma D. VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. Oncol Rep. 2007;18(1):241–7.PubMed

13.

Ochi N, Matsuo Y, Sawai H, Yasuda A, Takahashi H, Sato M, et al. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis. Pancreas. 2007;34(4):444–51.PubMedCrossRef

14.

Morita H, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Nishimura C, et al. Histopathological predictor for regional lymph node metastasis in gastric cancer. Virchows Arch. 2009;454(2):143–51. doi:10.1007/s00428-008-0717-3.PubMedCrossRef

15.

Gao P, Zhou GY, Zhang QH, Su ZX, Zhang TG, Xiang L, et al. Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol. 2009;218(2):192–200. doi:10.1002/path.2523.PubMedCrossRef

16.

Schoppmann S, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, et al. Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Tr. 2006;99(2):135–41. doi:10.1007/s10549-006-9190-3.CrossRef

17.

Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99(6):2179–84.PubMedCrossRef

18.

Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47(10):1511–20. doi:s0140-6736(03)13975-x/j.ejca.2011.04.006.PubMedCrossRef

19.

Grishok A, Tabara H, Mello CC. Genetic requirements for inheritance of RNAi in C. elegans. Science. 2000;287(5462):2494–7. doi:10.1126/science.287.5462.2494.PubMedCrossRef

20.

Pennati M, Millo E, Gandellini P, Folini M, Zaffaroni N. RNA interference-mediated validation of surviving and Apollon/BRUCE as new therapeutic targets for cancer therapy. Curr Top Med Chem. 2012;12(2):69–78. doi:10.1007/978-1-60327-547-7_15.PubMedCrossRef

21.

Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001;114(24):4557–65.PubMed

22.

Sui G, Soohoo C, el Affar B, Gay F, Shi Y, Forrester WC. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA. 2002;99(8):5515–20. doi:10.1073/pnas.082117599.PubMedCrossRef

23.

Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA. 2002;99(9):6047–52.PubMedCrossRef

24.

Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med. 2010;12:e26. doi:10.1017/S1462399410001584.PubMedCrossRef

25.

Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20(4):672–82. doi:10.1093/emboj/20.4.672.PubMedCrossRef

26.

Enholm B, Paavonen K, Ristimäki A, Kumar V, Gunji Y, Klefstrom J, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;14(20):2475–83.PubMedCrossRef

27.

Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, et al. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer. 2011;117(14):3135–47. doi:10.1002/cncr.25893.PubMedCrossRef

28.

Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, et al. Correlation of hypoxia inducible factor-1 alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol. 2005;78(2):123–30. doi:j.yexmp.2004.11.002/j.yexmp.2004.11.002.PubMedCrossRef

29.

Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61(9):746–59. doi:j.yexmp.2004.11.002/j.addr.2009.04.004.PubMedCrossRef

30.

Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res. 2011;28(12):2983–95. doi:10.1007/s11095-011-0604-5.PubMedCrossRef

31.

Polacheck WJ, Zervantonakis IK, Kamm RD. Tumor cell migration in complex microenvironments. Cell Mol Life Sci. 2012. doi:10.1007/s00018-012-1115-1.

32.

Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112(4):453–65. doi:j.yexmp.2004.11.002/S0092-8674(03)00120-X.PubMedCrossRef

33.

He M, Cheng Y, Li W, Liu QS, Liu JX, Huang JH, et al. Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. Cancer. 2010;10:1710. doi:10.1186/1471-2407-10-170.

34.

Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 2006;9(3):209–23. doi:j.yexmp.2004.11.002/j.ccr.2006.02.018.PubMedCrossRef

35.

Zhao R, Liu XQ, Wu XP, Liu YF, Zhang ZY, Yang GY, et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett. 2010;287(2):150–6. doi:j.yexmp.2004.11.002/j.canlet.2009.06.006.PubMedCrossRef

36.

Guo BL, Zhang YF, Luo GQ, Li LC, Zhang JG. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec Adv Integr Anat Evol Biol. 2009;292(5):633–9. doi:10.1002/ar.20893.CrossRef

Title: RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice
Authors: Jibin Yao
Mingxu Da
Tiankang Guo
Yaoxing Duan
Yongbin Zhang
Publication date: 01-06-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0674-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma

Glutathione S-transferase P1 Ile105Val polymorphism contributes to increased risk of gastric cancer in East Asians

Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma

TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors

The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis

RETRACTED ARTICLE: Association of GSTT1 gene polymorphisms with the risk of prostate cancer: an updating meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer